Health
NHS Rolls Out New Anti-Smoking Drug to Boost Quit Rates Amid Push for a Smoke-Free UK
England’s National Health Service (NHS) has reintroduced an enhanced anti-smoking drug, Varenicline, aimed at increasing success rates for those seeking to quit smoking. Marketed as a prescription-only treatment, Varenicline offers an effective alternative to nicotine-replacement therapies like gum or patches and is comparable to vaping in its ability to curb smoking habits, according to NHS England.
The drug, taken daily, is reported to both reduce nicotine cravings and block the pleasurable effects of smoking on the brain. By minimizing withdrawal symptoms such as irritability and insomnia, Varenicline is seen as a promising tool in the NHS’s suite of smoking cessation options. When paired with counseling or other psychotherapeutic support, NHS data suggests that around 25% of users successfully quit smoking for six months or longer.
The reintroduction of Varenicline is expected to have a substantial public health impact. Research from University College London (UCL) indicates that the drug could assist more than 85,000 people in quitting smoking each year and could prevent up to 9,500 smoking-related deaths over the next five years.
“Prevention is better than cure,” said Wes Streeting, the UK’s Health and Social Care Secretary, in a statement regarding the drug’s rollout. “The availability of this pill can save the NHS millions, speed up appointment availability for other patients, and save lives.”
Previously available under the brand name Champix, Varenicline was withdrawn from NHS prescriptions in 2021 due to the detection of an impurity. However, the newly launched version has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), confirming its safety and efficacy.
NHS Chief Executive Amanda Pritchard emphasized Varenicline’s role in the NHS’s preventive healthcare focus during a speech at the NHS Providers annual conference. “This simple daily pill could be a game-changer for those looking to quit smoking and marks another significant step toward prevention,” she said. “Smoking remains one of the biggest public health issues, impacting the lungs, heart, blood, and brain, and increasing the risk of serious conditions such as cancer and diabetes.”
The launch of Varenicline aligns with the UK’s broader anti-smoking goals, which include a proposed bill to prevent individuals born after January 1, 2009, from legally purchasing cigarettes. Currently, about 12% of adults in the UK smoke, a figure that correlates with over 400,000 smoking-related hospital admissions in England from 2022 to 2023.
The NHS already offers various smoking cessation options, including nicotine replacement therapies and the antidepressant Bupropion (Zyban), which has been shown to reduce cravings. While vaping is also commonly used, it remains unavailable through NHS prescriptions. The National Institute for Health and Care Excellence (NICE) instead recommends licensed stop-smoking medications like Varenicline.
Professor Nick Hopkinson, a respiratory medicine expert at Imperial College London, described Varenicline as “the most effective smoking cessation medication” and emphasized that pairing it with counseling support can improve quit success rates. Dr. Sarah Jackson, principal research fellow at the UCL Tobacco and Alcohol Research Group, added that Varenicline’s availability “can help more people avoid years of ill health and early death.”
With the NHS spending £2.5 billion annually on smoking-related health issues, the reintroduction of Varenicline is viewed as a cost-saving initiative with the potential to improve public health outcomes significantly. As the UK continues its push towards becoming smoke-free, Varenicline offers a new hope for smokers looking to quit and contribute to the nation’s ambitious health goals.
Health
More Europeans Take Up Sport, but Major Gaps Remain Across Countries
More Europeans are exercising regularly than they were four years ago, but participation continues to vary sharply depending on where people live, their age, education and financial circumstances, according to a new European Commission survey.
The latest Eurobarometer survey on sport and physical activity found that 39% of respondents said they never exercise or play sport, down from 45% in 2022. Nearly half of the 26,508 people surveyed said they exercise or play sport every day or several times a week.
The results also showed wide differences between countries. Finland recorded the highest share of people exercising daily, at 21%, followed by Denmark at 20%. In both countries, another 59% of respondents said they exercise several times a week.
At the other end of the scale, 68% of respondents in Portugal said they never exercise or play sport. Greece and Romania followed, with 66% in each country reporting that they never take part in sport or exercise.
Time was the most commonly cited barrier among people who wanted to exercise more, with 37% identifying it as an obstacle. A lack of motivation or interest was mentioned by 26%, while 15% pointed to health problems or injury. Cost was cited by 12%.
Education and household finances were also closely linked to participation. Some 59% of people who continued their education until at least the age of 20 said they exercise or play sport several times a week. That compared with 23% among those who left education at 15 or younger.
Financial circumstances showed a similar divide. People who said they had the greatest difficulty paying their bills were twice as likely to report never exercising as those who rarely or never faced financial difficulties, at 54% compared with 26%.
“More Europeans are getting active, but the opportunity to take part still depends too much on income, age and education,” said Roxana Mînzatu, Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness.
The survey also highlighted a significant age gap. Nearly three-quarters of people aged 15 to 24 exercise or play sport at least several times a week, compared with 25% of those aged 75 and over. Health problems or injury were the main barrier for older respondents, while younger and middle-aged people were more likely to cite a lack of time.
Physical activity linked to everyday life also increased. Active commuting rose from 24% in 2022 to 37%, while 72% of respondents said they now walk for at least 10 minutes at a time.
The survey found, however, that some Europeans do not consider their neighbourhoods suitable for walking or cycling, potentially restricting opportunities for active travel.
Mînzatu said affordable sport and safe places to exercise should be available close to where people live, including for children from families unable to afford club fees, older people and those with disabilities.
Health
Congenital Infections Linked to Higher Risks of Autism and Intellectual Disability
Children born with certain infections acquired during pregnancy face substantially higher risks of autism and intellectual disability later in life, according to a study of more than 3.7 million people in Sweden.
Researchers found that children with congenital infections were about three times more likely to be diagnosed with autism and more than seven times more likely to receive a diagnosis of intellectual disability than those without such infections.
The findings suggest that infections transmitted from a pregnant woman to her foetus may have lasting effects on brain development, although the study identifies an association rather than proving that the infections directly cause autism or intellectual disability.
The research focused on TORCH infections, a group that includes syphilis, rubella, toxoplasmosis, cytomegalovirus and herpesvirus. These infections can cross the placenta and affect the developing foetus, potentially increasing the risk of miscarriage, stillbirth and other pregnancy complications.
“Although these congenital infections are rare, some of them can be prevented, which makes them important from a public health perspective,” said Reneé Gardner of the Department of Global Public Health at Karolinska Institutet, who contributed to the study.
The researchers examined people born in Sweden between 1987 and 2021 and followed them for up to 30 years. Among the 3.7 million participants, 975 had been diagnosed with a congenital TORCH infection.
Although congenital infections accounted for only a small proportion of autism cases across the population, the risk among affected children was considerably higher. The researchers estimated that about one in five children born with a TORCH infection could later develop autism.
The study also found elevated risks of intellectual disability across different levels of severity. The risk of severe to profound intellectual disability was as much as 30 times higher among children with a congenital infection than among those without one.
The researchers found evidence of an impact on educational outcomes even among people who were not diagnosed with autism or intellectual disability. A total of 420 participants with a TORCH infection showed poor school performance without receiving either diagnosis.
Congenital cytomegalovirus, or CMV, is the most common of these infections globally and affects roughly one in 150 newborns. Its burden is substantially greater in low- and middle-income countries.
The researchers said the findings highlight the importance of prevention, particularly in regions where these infections are more common. They pointed to vaccination programmes and other preventive measures as important tools for reducing congenital infections.
They also called for improved identification of affected newborns. Current screening systems, including those used in Sweden, may miss asymptomatic infections because universal screening for TORCH infections is not routinely carried out.
The authors said stronger screening and prevention strategies could help identify children at risk earlier and improve long-term support and care.
Health
AI Chatbots Make Faster, Less Nuanced Kidney Transplant Decisions Than Doctors
Artificial intelligence chatbots may make faster and more confident decisions than human doctors when determining which patient should receive a life-saving kidney transplant, but a new study found that the systems often rely on fewer factors and show less sensitivity to the ethical complexity of such choices.
Researchers from Penn State University in the United States compared decisions made by large language models (LLMs) with choices made by people in earlier studies on kidney allocation. The researchers presented AI models with hypothetical cases based on existing datasets in which human participants had previously chosen between two patients competing for a single available kidney.
The patients were described using characteristics including age, health and drinking habits. Both were considered eligible for the transplant, requiring the decision maker to determine which patient should receive the available organ.
The researchers tested the AI systems in several ways. Some scenarios focused on individual characteristics, while others combined several traits to examine how the models handled competing considerations. In some tests, participants and AI systems were also given the option of flipping a coin, allowing researchers to assess indecision as part of moral decision-making.
Human participants generally placed greater importance on age, often favouring younger patients over older patients. Many of the AI models, however, placed greater weight on lower alcohol consumption.
Hadi Hosseini, the study’s lead researcher at Penn State University, said the findings showed that AI chatbots can diverge from human values when weighing characteristics of patients.
The researchers found that human decisions tended to consider several factors together and were more sensitive to context. LLMs, by contrast, frequently focused on a single characteristic when making their choices.
Another difference involved uncertainty. Human participants were more likely to recognise that organ allocation can involve competing ethical considerations and that there may not be one objectively correct answer. AI models generally showed little hesitation and committed to one choice.
John Dickerson, chief executive officer of Mozilla.ai and a collaborator on the study, said humans recognise ambiguity when allocating scarce resources and use debate to shape how such decisions are made.
The findings come as AI systems are increasingly being used in healthcare for clinical workflows, diagnosis, treatment planning and decisions involving limited medical resources.
The researchers said kidney allocation presents a particularly important test because decisions over deceased-donor and living-donor organs involve medical, ethical and moral considerations.
Hosseini said the ethical stakes are high because decisions involving organ allocation can directly affect patients’ lives. He stressed that the study was not intended to encourage replacing professional medical judgment with AI.
Instead, the researchers said understanding how AI systems behave in high-stakes situations is becoming increasingly important as individuals, organisations and businesses use AI to make decisions or provide recommendations.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement2 years agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
